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This article reviews the recent advances in the diagnosis and management of IgE mediated food allergy in children. It will encompass 
the emerging technology of component testing; moves to standardization of the allergy food challenge; permissive diets which 
allow for inclusion of extensively heated food allergens with allergen avoidance; and strategies for accelerating tolerance and food 
desensitization including the use of adjuvants for specific tolerance induction.
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DIAGNOSIS
The gold standard for the diagnosis of IgE mediated food 
allergy is the double-blind placebo-controlled food challenge 
(DBPCFC), but in reality this procedure is generally reserved 
for clinical trials. More commonly utilised are observed food 
challenges (OFC) usually unblinded to the administering clinician. 
These are particularly helpful where sensitisation to a food 
allergen is present – a positive skin prick test (SPT) or detection 
of serum specific IgE (ssIgE) – without a history of ingestion, 
or where the history of the ingestion is in doubt, or the history 
of symptoms resulting from the food ingestion is not highly 
suggestive of an IgE mediated reaction.
Most commonly, the clinical diagnosis of food allergy relies 
upon a convincing recent history of immediate objective 
symptoms, and the confirmation by detection of IgE production 
directed against the candidate food, either by SPT and/or by 
detection of ssIgE.
Two emerging trends have recently influenced the current 
diagnosis of food allergies, the evolution of component resolved 
diagnostics (CRD), and the move towards standardisation of 
protocols, severity indexes and agreed symptoms for OFC and 
DBPCFC.
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Component testing
Component testing or CRD aims, as the names suggest, to 
identify and quantitate IgE directed against specific (generally 
protein) components of each allergen as compared with traditional 
ssIgE or SPT which assess the presence of IgE to bind to the whole 
allergen protein sequence and therefore rely on crude allergen 
extracts. CRD can be performed through the detection of a 
specific single component of particular interest, such as omega-5-
gliadin in wheat dependant exercise induced anaphylaxis (WDEIA), 
in small panels such as Ara h 1, 2, 3, 8, and 9 in peanut allergy, or 
increasingly as a microarray, where a large number of recombinant 
and/or purified components are assayed simultaneously (examples 
include ISAC microarray).
Peanut
Peanut CRD has been studied most extensively; however 
its role in the diagnosis of peanut allergy, particularly outside 
Europe, remains unclear. Research has attempted to correlate 
reactivity to specific components with clinical allergy (as opposed 
to sensitisation alone) and/or severity of reaction, as this would 
improve the ability to prognosticate and reduce the need for 
OFC. In a number of studies to date Ara h 1, Ara h 2 and Ara h 3 
appear to be associated with a higher likelihood of true clinical 
allergy, whereas reactivity to Ara h 8 is associated with cross 
sensitisation to birch pollen, and less likely to be associated with 
significant clinical allergy [1]. Ara h 2, at cut-offs of > 0.1 kUA/
L had similar or slightly superior test characteristics (sensitivity, 
specificity, PPV) compared with SPT and ssIgE when examined 
in a cohort of Australian infants (12-15 months) with challenge-
proven peanut allergy. Importantly however, approximately 20% 
of infants with challenge-proven peanut allergy had no Ara h 2 
detected [2]. Similarly, even using all peanut components, ssIgE 
and complicated statistical algorithms, the misclassification rate of 
peanut allergy was still around 7% in a UK based study [3].
Ara h 9 is a member of the heat stable lipid transfer protein 
(LTP) family (also known as seed storage proteins), and appears to 
be a regionally important component, relating to cross- and co-
sensitisation with similar allergens found, for example, in peach 
allergic patients in Spain [4] and in oral allergy syndromes. Regional 
variations in which components appear important in clinical 
peanut allergy clearly demonstrate the importance of performing 
region specific studies, before extrapolation of European or North 
American data to the Asia-pacific region. Importantly, authors of 
CRD peanut studies generally conclude that detection of specific 
components does not rule in or out a clinically important allergy. 
Sicherer and Wood [5] have recently clearly outlined the situations 
in which CRD for peanut allergy is most likely to be informative in a 
comprehensive review of diagnosis of peanut allergy.
Other foods
CRD is useful in the diagnosis of WDEIA where omega-5-gliadin 
is the most commonly reported component [6]. Other foods have 
been examined less intensively. Associations have been identified 
between severity of reactions to soy and Gly m5 and Gly m6 [7]. 
Ovomuocid (Gal d1) has been associated with clinical reactivity 
and severity of reaction to extensively heated egg products such 
as baked cakes and muffins in egg allergic children [8, 9].
Summary statement CRD
The promise of a simple diagnostic test to allow for a highly 
accurate method of differentiating between clinical relevant IgE 
mediated allergy and sensitisation alone has yet to be fully realised. 
Clinicians must be mindful of the pitfalls of over-interpretation of 
Ara h 2 in particular, but this also applies to CRD for other food 
allergens. It is likely that as clinical phenotype/component profiles 
become more extensively defined and regional differences are 
better understood, more useful applications for CRD will emerge. 
With the current limited knowledge base, CRD microarray as a 
screen for potential sensitivities without a high index of suspicion 
for clinical allergy cannot be recommended. Currently, CRD may be 
best used judiciously in selected patients for diagnosis of peanut 
allergy where the a priori likelihood of clinical reactivity is relatively 
low before proceeding to OFC, in egg allergic children where 
extensive heated egg OFC is contemplated and in WDEIA. It has 
not replaced an OFC or DBPCFC in the diagnosis of food allergy.
Standardisation of food challenge protocols and 
guidelines
Oral food challenge is the gold standard in the diagnosis of 
food allergy and is also an important tool in safely demonstrating 
resolution of a known or proven food allergy. With the increasing 
prevalence of food allergy and testing for IgE sensitisation, and 
increasing data about decision points at which OFC may be offered 
for differing food sensitisations, a common uniform national and 
international standard for OFC is desirable. There have been several 
important moves towards standardisation of the OFC in recent 
years, which are helpful not only for clinical trials reporting and 
harmonising data across study sites and between trials, but also for 
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improving clinical practice. Standardisation of challenge protocols 
for particular foods, outlining exact food type and vehicle, dosage 
schedule and protein content of a complete challenge, will further 
improve our ability to diagnose and manage children with food 
allergy.
The 2012 PRACTALL “Standardizing double-blind, placebo-
controlled oral food challenges” report [10] is a consensus 
document produced by the AAAAI and EAACI and is an 
important step in the standardisation of all OFC. The report 
includes recommended minimum levels of safety, equipment 
and personnel, time to observe before discharge following a 
negative challenge, recommendation of semi-logarithmic dosage 
scheduling regimes and perhaps most importantly agreed 
objective criteria for determining a positive challenge reaction. A 
useful (although not validated) scoring criteria for IgE mediated 
acute allergic reactions on challenge is presented.
There is no international cross-regional consensus document for 
standardisation of OFC except the WAO DRACMA report [11], which 
is specific to cow’s milk allergy, but does outline recommendations 
for best practice OFC to cow’s milk in a variety of settings.
In our region, efforts to standardise food challenge protocols 
across countries such as Australia is occurring. The Australian 
Society for Allergy and Clinical Immunology (ASCIA) have now 
agreed challenge protocols for the most common food allergens, 
egg, baked egg, milk, wheat, peanut, soy and tree nuts (example 
of challenge protocol, Supplementary data 1) [12].
MANAGEMENT OF FOOD ALLERGY
The mainstay of management of children with food allergies 
has been allergen avoidance and provision of action/emergency 
management plans for accidental exposure to known food 
allergens (an example of an Australian [ASCIA] Management plan 
is shown in Supplementary data 2). In some instances this also 
involves the provision of an adrenaline auto injector. More recently, 
there is an emerging trend towards controlled exposure to the 
allergen in order to achieve specific tolerance induction, most 
commonly via the oral route (specific oral tolerance induction, 
SOTI), and for less restrictive diets for children with egg and milk 
allergy, with permissive incorporation of heat modified allergen in 
foods such as cakes and muffins.
Risk management of the food-allergic child
Food allergy is the commonest cause of anaphylaxis in children 
and can be fatal. Despite the increasing prevalence of food allergy 
and the incidence of food-induced anaphylaxis [13], the rate of 
fatal food anaphylaxis remains thankfully low [14, 15]. Nonetheless, 
allergic individuals and their families often perceive the risk of 
death to be much greater, resulting in a significant impact on their 
quality of life. This is partly because affected individuals (or their 
parents) interpret risk in a more emotion-led context while health 
professionals often take a rational, objective approach to risk [16].
Measures which may reduce risk of accidental exposure 
to known food allergens and food anaphylaxis include the 
provision of clear dietary avoidance instructions, easy-to-follow 
management plans and education in the use of adrenaline auto-
injector devices [17]. A recent study found that provision of 
adrenaline auto-injector devices increases the impact of the food 
allergy on quality-of-life measures, although there is an assumption 
that provision of these medications is an important in reducing the 
risks of a fatal anaphylactic reaction [18]. Unfortunately there are 
currently no reliable indicators to accurately predict which food-
allergic individuals are more at highest risk of fatal anaphylaxis. 
Case series fatal food anaphylaxis often quote asthma as a risk 
factor [14, 19] however the prevalence of asthma is so common 
that the predictive value for the individual patient is very poor.
There is a tendency to view food-allergic individuals who react 
to very small levels of allergen (i.e. who have a low eliciting dose 
or threshold of reactivity) as being more at risk of anaphylaxis. 
However, a large prospective series of peanut-allergic individuals 
undergoing DBPCFC did not demonstrate this to be the case [20].
Summary statement risk management
More research is needed to identify strategies to improve risk 
stratification of food-allergic individuals. Provision of an emergency 
plan and education regarding dietary avoidance strategies is 
recommended.
Extensively heat-treated allergens and permissive 
allergen exposure
Until recently, most allergy guidelines recommended strict 
avoidance of all forms and amounts of allergen for the diet of 
allergic children. This was partly on the basis of safety and also on 
the belief that that accidental allergen exposure may delay the 
onset of tolerance [21]. It is now widely held that this is unlikely to 
be the case, with a series of publication demonstrating that most 
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children allergic to egg and milk can tolerate extensively heated 
egg and milk in serving size quantities. This is likely to be related to 
changes in the ability of the allergen to bind specific IgE through 
heat denaturation of susceptible conformational epitopes. It may 
also relate to the interaction between the matrix components (such 
as wheat) and the egg proteins in baked cakes and goods [22].
There are two potential positive effects related the incorporation 
of extensively heat treated egg and milk in diets of egg and milk 
allergic children. The first is the lessening on dietary restrictions 
resulting in improved quality of life. The second is the potential 
for altering the natural history of the disease, and accelerating 
acquisition of tolerance to egg and/or milk.
Up to 70% of egg allergic children [23, 24] and milk allergic 
children [25] will tolerate extensively heated egg or milk in their 
diet at OFC, whilst still being allergic to the naïve protein. Higher 
ssIgE to ovomucoid appears to be associated with a higher 
likelihood to being unable to tolerate extensively heated egg 
in muffin or cake on OFC [8, 26]. Ovomucoid SPT wheal size of 
> 11 mm has been shown to be associated with more severe 
generalised allergic reaction on baked muffin OFC [9]. SPT size to 
egg over time was not shown to be different in children strictly 
avoiding egg compared with those with regular baked egg 
ingestion [27] in a recent Australian retrospective study. Although 
the British Society of Allergy and Clinical Immunology support 
a home baked egg challenge protocol for selected egg allergic 
children without a prior history of asthma [28], most other authors 
and experts recommend that these challenges still take place in a 
supervised setting, in view of the potential for anaphylaxis [9, 29].
Recently an association between the regular ingestion of 
clinically tolerated heat-treated egg [30] and milk [25] and a 
reduction in time to whole milk/egg tolerance has been described 
in two prospective studies on children consuming regular heated 
egg or milk following demonstration of tolerance at OFC. Whether 
this is due to regular ingestion of the heated allergen hastening 
resolution of the allergy is unknown, as it is possible that children 
who tolerate extensively heated egg/milk may outgrow their 
allergy more rapidly irrespective of exposure. Interestingly, these 
children demonstrate immunological changes consistent with the 
induction of tolerance, implying the former may be more likely 
[14, 20]. However as these studies were not randomised controlled 
trials, no conclusive recommendation can be made at this time to 
support this as a management strategy purely for the reason of 
accelerated tolerance.
Finally, although dietary incorporation of extensively-head 
modified allergens are likely to become standard practice over 
the next few years for children with egg and cow milk allergy, 
there have been a few concerning reports of the development 
of eosinophilic oesophagitis (EoE) following SOTI to egg [31] 
and milk [32]. It is possible that EoE could also be precipitated by 
incorporation of extensively heat-treated egg and milk. Therefore 
careful follow-up of such patients is advised, with particular 
attention to any emerging symptoms suggestive of EoE.
Summary statement
Extensively heated egg and milk: Up to 70% of children allergic 
to egg and cow’s milk can tolerate products containing extensively 
heated egg or milk, such as cake, baked cheese and biscuits. This 
liberalisation of the diet may have significant gains for patients 
and families and reduce anxiety around food avoidance. OFC to 
baked products should be performed in a supervised setting. 
Anaphylaxis may occur in those children even with a history of 
non-anaphylactic reactions to the native allergen, and in children 
without a history of asthma. Careful follow-up is recommended to 
monitor for any adverse effects.
Specific oral tolerance induction
Much l ike  t r ad i t iona l  sub cutane ous  and sub l ingual 
immunotherapy (SLIT) for aeroallergen allergy, immunotherapy 
for food allergy is based upon administration of gradually 
increases doses of allergen, most commonly via the oral route, 
with up-dosing and maintenances phases. Clinical trials to date 
have tended to be small, with egg, milk and peanut as the most 
frequently examined allergens. Most published studies have 
demonstrated a positive effect, although this may be due to 
a degree of reporting bias associated with negative studies. 
Primary outcomes have primarily assessed desensitization rather 
than sustained long term tolerance, and only a few more recent 
studies have conducted long term follow up [33, 34]. Those 
studies with follow up have generally shown disappointingly 
low rates of sustained tolerance, with the vast majority achieving 
only a temporary state of desensitisation which is rapidly lost 
without regular ongoing exposure to the allergen [33-35]. The 
current state of SOTI for food allergens has been comprehensively 
recently reviewed by several leading food allergy experts [36, 37]. 
A recent meta-analysis concluded that SOTI cannot currently be 
recommended for routine clinical practice and that larger, better 
designed RCTs are required [38].
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Egg
Several published studies have examined the efficacy and safety 
of desensitisation children to egg [34, 35]. The largest and most 
recent of these examined the effect of daily egg immunotherapy 
on 55 egg allergic and sensitised children [34]. The study was 
randomised and blinded during the initial up dosing and 
maintenance phase (10 months) until the time of the first oral 
challenge. Children undergoing active treatment continued 
receiving daily egg in an unblinded fashion until 22 months, were 
rechallenges and then had a further challenge following 2 months 
without daily egg. Overall 30 of 40 children were considered to 
have been desensitised, however only 11 of these children had 
sustained tolerance following 2 months without the daily egg 
therapy.
Milk
A 2012 meta-analysis [39] of 5 milk SOTI trials considered to be of 
suitable quality (out of a total of 16 RCT) concluded that although 
the quality of evidence was low, desensitisation was achieved in 
the majority of individuals treated but long term tolerance had not 
been shown, and that there was a high rate of adverse effects and 
lack of standardised protocols.
Peanut
A 2012 Cochrane review of SOTI for peanut allergy [40] found 
only one small peanut SOTI trial (n=28) [41] which satisfied 
inclusion criteria. SOTI appeared effective for desensitisation, but 
was associated with a high rate of adverse effects and the authors 
recommended larger RCT before SOTI for peanut allergy could be 
recommended.
SOTI with adjuvants
The potential to improve efficacy and safety and to decrease 
side effects in SOTI has prompted trials involving combination 
adjuvant and oral immunotherapy protocols.
Anti-IgE therapy and SOTI
Anti-IgE co-administered with milk SOTI has been investigated 
in a phase one study, and found to be associated with relatively 
few side effects and allowed desensitisation in the majority 
of participants [42]. The study requires confirmatory in larger 
cohorts within a well conducted RCTs. More studies are underway, 
and preliminary reports suggest a significant improvement 
in response to SOTI when used in conjunction with anti-IgE 
treatment [43]. Mechanistic studies have demonstrated deletion 
of allergen-specific T cells following high dose cow’s milk SOTI 
and omalizumab therapy, suggesting a plausible rationale for the 
long term tolerance which is hoped to be obtained using this 
combination therapy [44].
Probiotics and SOTI
The potential of probiotics co-administered with oral food 
allergens has been investigated in the murine model where 
efficacy and protection against experimentally induced food 
anaphylaxis has been demonstrated [45]. A current clinical 
trial is underway in a Melbourne based RCT (P-POIT study, 
ACTRN12608000594325) examining the effectiveness of probiotics 
and peanut SOTI (P-POIT) in children with peanut allergy.
SOTI- Summary statement
The largest SOTI studies to date have shown ef fective 
desensitisation for the majority of patients so long as frequent 
exposure to the allergen is continued. Sustained tolerance only 
occurs in a minority of subjects, where long term follow-up has 
occurred, and this is a significant limitation in its future clinical 
safety and utility. SOTI requires active and compliant adherence 
and a willingness to fully participate from patients and their 
families, and this too may limit its ultimate translational potential. 
The use of adjuvants in association with SOTI to improve efficiency 
and safety and decrease side effects is appealing, but not yet 
proven. Despite the promise of SOTI over the past decade, we 
are yet to have a reliable, safe, easily-administered SOTI protocol 
suitable for routine clinical practice in 2013.
Other immunotherapy routes
The finding that patients undergoing birch SLIT were noted to 
have improvement in their oral allergy symptoms [46] led to the 
possibility that SLIT might be an effective route for the treatment 
of other food allergies, where the primary sensitising agents is not 
an aeroallergen. Small clinical trials utilising food-based SLIT have 
now shown some efficacy by increasing threshold eliciting doses 
for allergic reactions to hazelnut [47], peanut [48] and kiwi fruit 
[49]. Most recently, the trans-epithelial route has been reported in 
a trial of milk allergic children [50], however no change was noted 
in the subsequent eliciting dose between control and intervention 
groups.
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Other therapies
Currently under investigation are Chinese herbal preparations, 
which have been examined at the Mount Sinai centre in New York 
and collaborating institutions for some years. There is encouraging 
animal data where the herbal mixture FAHF-2 was demonstrated 
to completely block experimentally induced peanut anaphylaxis in 
sensitised mice [51]. Phase 2 human studies are now underway [52].
Allergen-specific T-cell epitopes are targets for a novel potential 
therapy in food allergy which seeks to induce immunomodulation 
and oral tolerance by administration of short T-cell epitope 
peptides, which can target allergen specific T cells without binding 
IgE. Animal models have demonstrated efficacy [53, 54], and 
desensitisation has been trialled in human subjects with insect and 
cat allergy but not, as yet, in food allergy. Promisingly, candidate 
T cell epitopes for peanut have been identified and research is 
ongoing [55].
SUMMARY
With the increasing worldwide prevalence of food allergy comes 
a renewed impetus for improving diagnosis and management. 
Standardisation of protocols and definitions will assist in the 
harmonisation and pooling of clinical trial data from disparate sites, 
and will provide higher quality evidence for both diagnosis and 
management of paediatric food allergy. Liberalisation of allergen 
avoidance diets can improve not only the quality of life of children 
with food allergy, but may hasten their tolerance acquisition. Over 
the next few decades it is likely that immunotherapy for food 
allergy will become a standard clinical tool with use of adjuvant 
co-administration, and will lead to long term sustained tolerance.
SUPPLEMENTARY DATA
Supplementary data are available from: http://apallergy.org/src/
sm/apa-3-88-s001.pdf.
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